Ultragenyx Pharmaceutical's GAAP loss for 3 months of 2022 was $152.32 million, up 11.9% from $136.141 million in the previous year. Revenue decreased 19.6% to $79.935 million from $99.395 million a year earlier.
Ultragenyx Pharmaceutical's GAAP loss for 3 months of 2022 was $152.32 million, up 11.9% from $136.141 million in the previous year. Revenue decreased 19.6% to $79.935 million from $99.395 million a year earlier. 
ir.ultragenyx.com
English (US) 